請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55570完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王若松(Juo-Song Wang) | |
| dc.contributor.author | Huey-Jen Wang | en |
| dc.contributor.author | 王惠禎 | zh_TW |
| dc.date.accessioned | 2021-06-16T04:10:03Z | - |
| dc.date.available | 2019-10-15 | |
| dc.date.copyright | 2014-10-15 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-21 | |
| dc.identifier.citation | Aghaloo, T. L., A. L. Felsenfeld and S. Tetradis (2010). 'Osteonecrosis of the jaw in a patient on Denosumab.' Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons 68(5): 959.
Allen, M. R. and D. B. Burr (2008). 'Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.' Journal of Oral and Maxillofacial Surgery 66(5): 987-994. Assaf, A. T., R. Smeets, B. Riecke, E. Weise, A. Groebe, M. Blessmann, T. Steiner, J. Wikner, R. E. Friedrich and M. Heiland (2013). 'Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.' Anticancer research 33(9): 3917-3924. Bagan, J., C. Scully, V. Sabater and Y. Jimenez (2009). 'Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update.' Oral oncology 45(7): 551-554. Barandier, C., X.-F. Ming and Z. Yang (2003). 'Small G proteins as novel therapeutic targets in cardiovascular medicine.' Physiology 18(1): 18-22. Bauer, J. S., N. Beck, J. Kiefer, P. Stockmann, M. Wichmann and S. Eitner (2012). 'Awareness and education of patients receiving bisphosphonates.' Journal of Cranio-Maxillofacial Surgery 40(3): 277-282. Benford, H. L., J. C. Frith, S. Auriola, J. Monkkonen and M. J. Rogers (1999). 'Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.' Molecular pharmacology 56(1): 131-140. Bi, Y., Y. Gao, D. Ehirchiou, C. Cao, T. Kikuiri, A. Le, S. Shi and L. Zhang (2010). 'Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.' The American journal of pathology 177(1): 280-290. Black, D. M., M. P. Kelly, H. K. Genant, L. Palermo, R. Eastell, C. Bucci-Rechtweg, J. Cauley, P. C. Leung, S. Boonen and A. Santora (2010). 'Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.' New England Journal of Medicine 362(19): 1761-1771. Coleman, R. E., H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, M. Keane, M. Gil, S. J. Houston, R. J. Grieve and P. J. Barrett-Lee (2011). 'Breast-cancer adjuvant therapy with zoledronic acid.' New England Journal of Medicine 365(15): 1396-1405. Cordero da Luz, F. A., A. P. Lima Oliveira, D. Borges, P. Cristina Brigido and M. J. Barbosa Silva (2014). 'The Physiopathological Role of IL-33: New Highlights in Bone Biology and a Proposed Role in Periodontal Disease.' Mediators of inflammation 2014. Coxon, F. and M. Rogers (2003). 'The role of prenylated small GTP-binding proteins in the regulation of osteoclast function.' Calcified tissue international 72(1): 80-84. Damm, D. D. and D. M. Jones (2013). 'Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays.' Gen Dent 61(5): 33-38. DE IULIIS, F., L. TAGLIERI, L. AMOROSO, S. VENDITTOZZI, L. BLASI, G. SALERNO, R. LANZA and S. SCARPA (2014). 'Prevention of Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates.' Anticancer research 34(5): 2477-2480. Deal, C. (2009). 'Potential new drug targets for osteoporosis.' Nature Clinical Practice Rheumatology 5(1): 20-27. Deng, X., R. Tamai, Y. Endo and Y. Kiyoura (2009). 'Alendronate augments interleukin-1β release from macrophages infected with periodontal pathogenic bacteria through activation of caspase-1.' Toxicology and applied pharmacology 235(1): 97-104. Dimopoulos, M. A., E. Kastritis, A. Anagnostopoulos, I. Melakopoulos, D. Gika, L. A. Moulopoulos, C. Bamia, E. Terpos, K. Tsionos and A. Bamias (2006). 'Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.' haematologica 91(7): 968-971. Durie, B., M. Katz and J. Crowley (2005). 'Osteonecrosis of the jaw and bisphosphonates.' N Engl j Med 353(1): 99-102. Fabbri, A., S. Travaglione and C. Fiorentini (2010). 'Escherichia coli cytotoxic necrotizing factor 1 (CNF1): toxin biology, in vivo applications and therapeutic potential.' Toxins 2(2): 283-296. Fisher, J., M. Rogers, J. Halasy, S. Luckman, D. Hughes, P. Masarachia, G. Wesolowski, R. Russell, G. Rodan and A. Reszka (1999). 'Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.' Proceedings of the National Academy of Sciences 96(1): 133-138. Fujita, H., S. Shimotsuura, A. Yanagisawa, I. Morita, S.-i. Murota and K. Ishikawa (2000). 'Simvastatin enhanced sodium nitroprusside-induced apoptosis of smooth muscle cells: an involvement of geranylgeraniol.' Atherosclerosis 148(2): 309-315. Funari, S. S., J. Prades, P. V. Escriba and F. Barcelo (2005). 'Farnesol and geranylgeraniol modulate the structural properties of phosphatidylethanolamine model membranes.' Molecular membrane biology 22(4): 303-311. Green, J., G. Czanner, G. Reeves, J. Watson, L. Wise and V. Beral (2010). 'Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.' BMJ 341. Guarneri, V., E. Barbieri, M. Dieci, F. Piacentini and P. Conte (2010). 'Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.' Cancer treatment reviews 36: S62-S66. Hansen, P. J., M. Knitschke, F. G. Draenert, S. Irle and A. Neff (2013). 'Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment—a grossly underestimated risk?' Clinical oral investigations 17(8): 1829-1837. Hasegawa, Y., M. Kawabe, H. Kimura, K. Kurita, J. Fukuta and M. Urade (2012). 'Influence of dentures in the initial occurrence site on the prognosis of bisphosphonate-related osteonecrosis of the jaws: a retrospective study.' Oral surgery, oral medicine, oral pathology and oral radiology 114(3): 318-324. Hasmim, M., G. Bieler and C. Ruegg (2007). 'Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation‐dependent signaling pathways.' Journal of Thrombosis and Haemostasis 5(1): 166-173. Hayama, K., M. Tsuchimochi, H. Yamaguchi, T. Oda, M. Sue, A. Kameta and Y. Sasaki (2013). 'Dynamic analysis of technetium-99m HMDP accumulation and its effect on regional bone metabolism and bone blood flow in bisphosphonate-related osteonecrosis of the jaw.' Oral Radiology 29(2): 135-139. Hellstein, J. W., R. A. Adler, B. Edwards, P. L. Jacobsen, J. R. Kalmar, S. Koka, C. A. Migliorati and H. Ristic (2011). 'Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis.' J Am Dent Assoc 142(11): 1243-1251. Hoff, A. O., B. B. Toth, K. Altundag, M. M. Johnson, C. L. Warneke, M. Hu, A. Nooka, G. Sayegh, V. Guarneri and K. Desrouleaux (2008). 'Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.' Journal of Bone and Mineral Research 23(6): 826-836. Hughes, A., M. J. Rogers, A. I. Idris and J. C. Crockett (2007). 'A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.' Calcified tissue international 81(5): 403-413. Huja, S. S., S. A. Fernandez, K. J. Hill and Y. Li (2006). 'Remodeling dynamics in the alveolar process in skeletally mature dogs.' The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology 288(12): 1243-1249. Hutagalung, A. H. and P. J. Novick (2011). 'Role of Rab GTPases in membrane traffic and cell physiology.' Physiological reviews 91(1): 119-149. Jacobsen, C., P. Metzler, J. A. Obwegeser, W. Zemann and K. W. Graetz (2012). 'Osteopathology of the jaw associated with bone resorption inhibitors: what have we learned in the last 8 years.' Swiss Med Wkly 142: w13605. Kuhl, S., C. Walter, S. Acham, R. Pfeffer and J. T. Lambrecht (2012). 'Bisphosphonate-related osteonecrosis of the jaws–a review.' Oral oncology 48(10): 938-947. Keller, E. and L. Gunderson (1987). 'Bone disease metastatic to the jaws.' Journal of the American Dental Association (1939) 115(5): 697-701. Khosla, S., D. Burr, J. Cauley, D. W. Dempster, P. R. Ebeling, D. Felsenberg, R. F. Gagel, V. Gilsanz, T. Guise and S. Koka (2007). 'Bisphosphonate‐associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.' Journal of Bone and Mineral Research 22(10): 1479-1491. Kim, D. W., Y.-S. Jung, H.-S. Park and H.-D. Jung (2013). 'Osteonecrosis of the jaw related to everolimus: a case report.' British Journal of Oral and Maxillofacial Surgery 51(8): e302-e304. King, A. E. and E. M. Umland (2008). 'Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.' Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28(5): 667-677. Kiyama, T., S. Okada, Y. Tanaka, S. Kim, K. Bando, M. Hasegawa, K. Yamaguchi, T. Takano-Yamamoto, K. Sasaki and S. Sugawara (2013). 'Inflammatory and Necrotic Effects of Minodronate, a Nitrogen-Containing Bisphosphonate, in Mice.' The Tohoku journal of experimental medicine 230(3): 141-149. Kyrgidis, A. and S. Triaridis (2009). 'Regular dental check-ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding'risks and benefits of bisphosphonates'.' British journal of cancer 100(4): 670. Kyrgidis, A. and K. Vahtsevanos (2009). 'Risk factors for bisphosphonate-related osteonecrosis of the jaws.' Journal of oral and maxillofacial surgery 67(11): 2553-2554. Kyrgidis, A. and K. Vahtsevanos (2010). 'Osteonecrosis of the jaw in patients receiving oral bisphosphonates.' Osteoporosis international 21(3): 535-536. Landesberg, R., M. Cozin, S. Cremers, V. Woo, S. Kousteni, S. Sinha, L. Garrett-Sinha and S. Raghavan (2008). 'Inhibition of oral mucosal cell wound healing by bisphosphonates.' Journal of Oral and Maxillofacial Surgery 66(5): 839-847. Lazarchik, D. A. (2013). 'Update on Bisphosphonate Osteonecrosis of the Jaws.' Lazarovici, T. S., S. Mesilaty-Gross, I. Vered, C. Pariente, H. Kanety, N. Givol, R. Yahalom, S. Taicher and N. Yarom (2010). 'Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.' Journal of Oral and Maxillofacial Surgery 68(9): 2241-2247. Lazarovici, T. S., R. Yahalom, S. Taicher, D. Schwartz-Arad, O. Peleg and N. Yarom (2010). 'Bisphosphonate-related osteonecrosis of the jaw associated with dental implants.' Journal of Oral and Maxillofacial Surgery 68(4): 790-796. Mucke, T., J. Koschinski, H. Deppe, S. Wagenpfeil, C. Pautke, D. A. Mitchell, K.-D. Wolff and F. Holzle (2011). 'Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws.' Journal of cancer research and clinical oncology 137(5): 907-913. Monkkonen, H., S. Auriola, P. Lehenkari, M. Kellinsalmi, I. E. Hassinen, J. Vepsalainen and J. Monkkonen (2006). 'A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen‐containing bisphosphonates.' British journal of pharmacology 147(4): 437-445. Marx, R. E., Y. Sawatari, M. Fortin and V. Broumand (2005). 'Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.' Journal of oral and maxillofacial surgery 63(11): 1567-1575. McLeod, D. E., M. Gautam, E. Reyes, C. Pandarakalam and B. A. Seyer 'Clinical Advances in Periodontics—Vol. 4, No. 2, May 2014.' Moinzadeh, A. T., H. Shemesh, N. Neirynck, C. Aubert and P. Wesselink (2013). 'Bisphosphonates and their clinical implications in endodontic therapy.' International endodontic journal 46(5): 391-398. Moon, H., M. M. Hill, M. J. Roberts, R. A. Gardiner and A. J. Brown (2014). 'Statins: protectors or pretenders in prostate cancer?' Trends in Endocrinology & Metabolism 25(4): 188-196. Naik, N. H. and T. A. Russo (2009). 'Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces.' Clinical infectious diseases 49(11): 1729-1732. Otto, S., M. H. Abu-Id, S. Fedele, P. H. Warnke, S. T. Becker, A. Kolk, T. Mucke, G. Mast, R. Kohnke and E. Volkmer (2011). 'Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence–a multi-centre study.' Journal of Cranio-Maxillofacial Surgery 39(4): 272-277. Otto, S., S. Hafner, G. Mast, T. Tischer, E. Volkmer, M. Schieker, S. R. Sturzenbaum, E. von Tresckow, A. Kolk and M. Ehrenfeld (2010). 'Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?' Journal of Oral and Maxillofacial Surgery 68(5): 1158-1161. Otto, S., C. Schreyer, S. Hafner, G. Mast, M. Ehrenfeld, S. Sturzenbaum and C. Pautke (2012). 'Bisphosphonate-related osteonecrosis of the jaws–characteristics, risk factors, clinical features, localization and impact on oncological treatment.' Journal of Cranio-Maxillofacial Surgery 40(4): 303-309. Park-Wyllie, L. Y., M. M. Mamdani, D. N. Juurlink, G. A. Hawker, N. Gunraj, P. C. Austin, D. B. Whelan, P. J. Weiler and A. Laupacis (2011). 'Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.' Jama 305(8): 783-789. Petcu, E. B., S. Ivanovski, R. G. Wright, M. Slevin, R. I. Miroiu and K. Brinzaniuc (2012). 'Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect.' Diagn Pathol 7(1): 78. Qi, W. X., A. N. He, Z. Shen and Y. Yao (2013). 'Incidence and risk of hypertension with a novel multi‐targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta‐analysis.' British journal of clinical pharmacology 76(3): 348-357. Reid, I. R., M. J. Bolland and A. B. Grey (2007). 'Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?' Bone 41(3): 318-320. Reszka, A. A. and G. A. Rodan (2003). 'Mechanism of action of bisphosphonates.' Current osteoporosis reports 1(2): 45-52. Ripamonti, C., M. Maniezzo, T. Campa, E. Fagnoni, C. Brunelli, G. Saibene, C. Bareggi, L. Ascani and E. Cislaghi (2008). 'Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.' Annals of Oncology: mdn526. Rizzoli, R., N. Burlet, D. Cahall, P. D. Delmas, E. F. Eriksen, D. Felsenberg, J. Grbic, M. Jontell, R. Landesberg and A. Laslop (2008). 'Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.' Bone 42(5): 841-847. Rogers, T. L. and I. Holen (2011). 'Tumour macrophages as potential targets of bisphosphonates.' J Transl Med 9(177): 5876-5879. Rubegni, P. and M. Fimiani (2006). 'Bisphosphonate-associated contact stomatitis.' New England Journal of Medicine 355(22). Ruggiero, S. L. (2009). 'Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development.' Journal of Oral and Maxillofacial Surgery 67(5): 13-18. Ruggiero, S. L. (2011). 'Bisphosphonate‐related osteonecrosis of the jaw: an overview.' Annals of the New York Academy of Sciences 1218(1): 38-46. Ruggiero, S. L., T. B. Dodson, L. A. Assael, R. Landesberg, R. E. Marx and B. Mehrotra (2009). 'American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate‐Related Osteonecrosis of the Jaw–2009 Update.' Australian endodontic journal 35(3): 119-130. Ruggiero, S. L., T. B. Dodson, J. Fantasia, R. Goodday, T. Aghaloo, B. Mehrotra and F. O’Ryan (2014). 'American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update.' Journal of Oral and Maxillofacial Surgery. Saad, F., D. M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J. L. Chin, J. J. Vinholes, J. A. Goas and B. Chen (2002). 'A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.' Journal of the National Cancer Institute 94(19): 1458-1468. Saia, G., S. Blandamura, G. Bettini, A. Tronchet, A. Totola, G. Bedogni, G. Ferronato, P. F. Nocini and A. Bedogni (2010). 'Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction.' Journal of Oral and Maxillofacial Surgery 68(4): 797-804. Sarin, J., S. DeRossi and S. Akintoye (2008). 'Updates on bisphosphonates and potential pathobiology of bisphosphonate‐induced jaw osteonecrosis.' Oral diseases 14(3): 277-285. Schindeler, A., M. M. McDonald, P. Bokko and D. G. Little (2008). Bone remodeling during fracture repair: The cellular picture. Seminars in cell & developmental biology, Elsevier. Sharma, D., S. Ivanovski, M. Slevin, S. Hamlet, T. S. Pop, K. Brinzaniuc, E. B. Petcu and R. I. Miroiu (2013). 'Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect.' Vasc Cell 5(1): 1. Stadeker, W. J. (2008). 'Bisphosphonates 101: an update for the general dentist.' Inside Dentistry Oct: 2-6. Stam, R. W., M. L. den Boer, J. P. Meijerink, M. E. Ebus, G. J. Peters, P. Noordhuis, G. E. Janka-Schaub, S. A. Armstrong, S. J. Korsmeyer and R. Pieters (2003). 'Differential mRNA expression of Ara-C–metabolizing enzymes explains Ara-C sensitivity in MLL gene–rearranged infant acute lymphoblastic leukemia.' Blood 101(4): 1270-1276. Stefanik, D., J. Sarin, T. Lam, L. Levin, P. Leboy and S. Akintoye (2008). 'Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate.' Oral diseases 14(5): 465-471. Takai, Y., T. Sasaki and T. Matozaki (2001). 'Small GTP-binding proteins.' Physiological reviews 81(1): 153-208. Tanaka, S.-i., Y. Fukumoto, K. Nochioka, T. Minami, S. Kudo, N. Shiba, Y. Takai, C. L. Williams, J. K. Liao and H. Shimokawa (2013). 'Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.' Arteriosclerosis, thrombosis, and vascular biology 33(7): 1591-1600. Tang, X., Q. Zhang, S. Shi, Y. Yen, X. Li, Y. Zhang, K. Zhou and A. D. Le (2010). 'Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells.' International Journal of Cancer 126(1): 90-103. Tolstunov, L., D. Cox and B. Javid (2011). 'Odontogenic Osteomyelitis or Bisphosphonate-Related Osteonecrosis of Mandible of Patient with Autoimmune Disease: Clinical Dilemma.' Compendium of continuing education in dentistry (Jamesburg, NJ: 1995) 33(10): E116-E122. Vahtsevanos, K., A. Kyrgidis, E. Verrou, E. Katodritou, S. Triaridis, C. G. Andreadis, I. Boukovinas, G. E. Koloutsos, Z. Teleioudis and K. Kitikidou (2009). 'Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.' Journal of Clinical Oncology 27(32): 5356-5362. Van Beek, E., C. Lowik, G. Van Der Pluijm and S. Papapoulos (1999). 'The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen‐Containing Bisphosphonates.' Journal of Bone and Mineral Research 14(5): 722-729. Vescovi, P. and S. Nammour (2010). 'Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review.' Minerva stomatologica 59(4): 181-203, 204-113. Watters, A. L., H. J. Hansen, T. Williams, J. F. Chou, E. Riedel, J. Halpern, S. Tunick, G. Bohle, J. M. Huryn and C. L. Estilo (2013). 'Intravenous bisphosphonate–related osteonecrosis of the jaw: Long-term follow-up of 109 patients.' Oral surgery, oral medicine, oral pathology and oral radiology 115(2): 192-200. Wilkinson, G. S., Y.-F. Kuo, J. L. Freeman and J. S. Goodwin (2007). 'Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis.' Journal of the National Cancer Institute 99(13): 1016-1024. Wutzl, A., S. Pohl, I. Sulzbacher, R. Seemann, G. Lauer, R. Ewers, J. Drach and C. Klug (2012). 'Factors influencing surgical treatment of bisphosphonate‐related osteonecrosis of the jaws.' Head & neck 34(2): 194-200. Yamazaki, T., M. Yamori, T. Ishizaki, K. Asai, K. Goto, K. Takahashi, T. Nakayama and K. Bessho (2012). 'Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study.' International journal of oral and maxillofacial surgery 41(11): 1397-1403. Yin, G., Y. Bai and E. Luo (2011). 'Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw.' Medical hypotheses 76(3): 347-349. Yoneda, T., H. Hagino, T. Sugimoto, H. Ohta, S. Takahashi, S. Soen, A. Taguchi, S. Toyosawa, T. Nagata and M. Urade (2010). 'Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Japanese society of oral and maxillofacial surgeons.' Journal of bone and mineral metabolism 28(4): 365-383. Ziebart, T., F. Koch, M. Klein, J. Guth, J. Adler, A. Pabst, B. Al-Nawas and C. Walter (2011). 'Geranylgeraniol–a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.' Oral oncology 47(3): 195-201. 王翰偉 (2013). '以 TRAP 染色探討雙磷酸鹽對蝕骨細胞及骨骼再生之影響-斑馬魚尾鰭再生模式.' 臺灣大學臨床牙醫學研究所學位論文: 1-81. 吳俊學 (2010). '利用斑馬魚活體實驗來探討雙磷酸鹽造成顎骨壞死之可能機制.' 李正喆 and 陳羿貞 (2009). '雙磷酸鹽類藥物相關顎骨壞死與牙科治療之關聯性.' 中華民國家庭牙醫學雜誌 4(2): 8-13. 張玲瑜 (2011). '探討影響雙磷酸鹽類藥物相關顎骨壞死 發生的風險因子及治療的預後因子.' 臺灣大學臨床牙醫學研究所學位論文: 1-114. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55570 | - |
| dc.description.abstract | 雙磷酸鹽類藥物引起之顎骨壞死是雙磷酸鹽治療主要副作用之一。至今，尚未有對於BRONJ的有效治療方式。含氮雙磷酸鹽（N-BPS）抑制焦磷酸合酶（FPPS）在mevalonate pathway（MVP）。香葉基香葉醇（GGOH）和香葉醇(FOH)代謝產物的下降被認為是顎骨壞死的主要因素。先前的體外研究已經顯示含氮雙磷酸鹽(N-BP)中的負面影響，降低不同類型的細胞的生存力和遷移的能力。本研究的目的是要測試，下游代謝產物的應用可以逆轉含氮雙磷酸鹽中負面的生物學效應。
我們利用斑馬魚的鰭再生模型探討其影響，試圖以mevalonate pathway下游生化產物在野生種(wild type) 斑馬魚中進行挽救實驗(rescue experiment)，進行更細微之觀察及研究。並利用抗酒石酸磷酸酶(Tartrate-resistant acid phosphatase, TRAP)的特性作為呈色的方法，標定活體內的蝕骨細胞，藉此觀察在香葉基香葉醇(geranylgeraniol, GGOH) 和香葉醇(FOH)的影響下，蝕骨細胞受到的影響。 本實驗首先利用calcein活體染色來觀察此藥物對成魚尾鰭切除後再生之型態是否有影響。再利用TRAP呈色法，觀察斑馬魚截切尾鰭後，蝕骨細胞之活化時間、移動方向的動態變化。藉以釐清活體魚之蝕骨細胞及尾鰭鰭條骨再生如何受香葉基香葉醇的影響。 實驗結果顯示，尾鰭再生觀察發現TRAP的呈色，雙磷酸鹽會抑制蝕骨細胞表現，甚至影響其活性。而香葉基香葉醇(geranylgeraniol, GGOH) 和香葉醇(FOH)對尾鰭再生部分發現骨質再生具有顯著影響，具有促進骨質生成作用。其結果可進一步延伸到在治療BRONJ的臨床應用。本次研究發現geranylgeraniol(GGOH)的調節蝕骨細胞的處理，更凸顯了GGOH的重要性，其臨床應用是進一步研究的課題。 | zh_TW |
| dc.description.abstract | Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is one of the main side effects of bisphosphonate therapy (BPT). To date, there is no effective therapy of the BRONJ. Nitrogen-containing bisphosphonates (N-BPs) target to the inhibition of pyrophosphate synthase (FPPS) in the mevalonate pathway. Consequently, decreased synthesis of the downstream metabolites, geranylgeraniol (GGOH) and farnesol (FOH), is believed to largely account for the development of BRONJ. Previous in vitro studies have shown the negative effects of N-BPs on decreased viability and migration capacity of different cell types. The aim of our study was to demonstrate that the application of downstream metabolites may reverse the negative biological effects of N-BPs.
Amputation-regeneration model of zebrafish caudal fin was employed to analyze the effects of drug administration. Alendronate (N-BP), farnesol, and geranylgeraniol at 7.5×10-5M were used to treat the fish by incubation. The regenerated bones in the fin were documented by calcein staining. The dynamic appearance of ostelclasts during the process was observed by TRAP staining. The bone regeneration impaired by alendronate was reversed to normal in the presence of GGOH and FOH. In addition, the morphological restoration was delineated by TRAP staining to reveal the distribution of osteoclasts. The results showed that the number and distribution of osteoclasts were restored to normal likewise. Hence, systemic application of GGOH and FOH may reduce the side effects of bisphosphonate therapy. In this study, we demonstrate that the impairing effects of alendronate on bone regeneration and osteoclast activities may be reversed by application of GGOH and FOH. Our study in zebrafish provides a vivid animal model to investigate the BRONJ in vivo. And the results may further extend to the clinical applications in treating BRONJ. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T04:10:03Z (GMT). No. of bitstreams: 1 ntu-103-P00422004-1.pdf: 5012947 bytes, checksum: 463333a1476d932bf6c7f7bb8028fc20 (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 口試委員審定書.....……………………………………………………i
誌謝……………………………………………………………………..ii 中文摘要…………………………………………………………….…iii 英文摘要…………………………………………………………….....v 壹、引言………………………………………………………………..1 貳、文獻回顧…………………………………………………………..3 參、實驗材料………………………………………………………….55 肆、實驗方法………………………………………………………….59 伍、結果……………………………………………………………….64 陸、結論與討論……………………………………………………….71 柒、未來展望………………………………………………………….87 捌、圖表……………………………………………………………….89 參考文獻………………………………………………………………108 | |
| dc.language.iso | zh-TW | |
| dc.title | 利用葉基香葉醇挽救斑馬魚尾鰭再生時因雙磷酸鹽損害細胞之功能 | zh_TW |
| dc.title | Use of geranylgeraniol (GGOH) to rescue bone regeneration impaired by bisphosphonate-- an in vivo study | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 張百恩(Bei-En Chang) | |
| dc.contributor.oralexamcommittee | 洪志遠(Chih-Yuan Hong) | |
| dc.subject.keyword | 雙磷酸鹽,顎骨壞死,挽救,香葉基香葉醇,斑馬魚, | zh_TW |
| dc.subject.keyword | bisphosphonate,BRONJ,rescue,GGOH,zebrafish, | en |
| dc.relation.page | 118 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-21 | |
| dc.contributor.author-college | 牙醫專業學院 | zh_TW |
| dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床牙醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 目前未授權公開取用 | 4.9 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。